Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Wang, Jiabing; Xu, Haoqian; Wang, Ying; Lin, Feng; Yi, Fengming

doi:10.1155/2023/5492931

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Locoregional therapy has been validated to improve the effectiveness of monotherapy of systematic treatment for advanced HCC [ 24 , 26 , 36 , 37 ]. For locoregional therapy, TACE and HAIC are the main options for advanced HCC [ 38 ]. However, HAIC is superior to TACE for patients with large HCC or unresectable [ 39 – 42 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

Zhang,

et al. 2024

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Background and aims The prognosis of hepatocellular carcinoma (HCC) with macrovascular invasion(MaVI)is poor, and the treatment is limited. This study aims to explore the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC), combined with lenvatinib and programmed cell death-1(PD-1) inhibitor in the first-line treatment of HCC with MaVI. Methods From July 2020 to February 2022, we retrospectively analyzed consecutive patients with HCC with MaVI who received hepatic arterial infusion FOLFOX(oxaliplatin, 5-fluorouracil, and leucovorin)combined with lenvatinib and PD-1 inhibitor. The efficacy was evaluated by RECIST 1.1. Kaplan-Meier was used to explore the overall survival and progression-free survival (PFS), and the COX regression model was used to analyze the risk factors of PFS. Adverse events (AEs) were evaluated according to CTCAE5.0. Results Thirty-two patients with HCC complicated with MaVI were recruited from the Second Affiliated Hospital of Nanchang University. Among the patients treated with HAIC combined with lenvatinib and PD-1 inhibitor, ten patients (31.25%) got partial response, eighteen patients (56.25%) maintained stable disease and four patients (12.50%) suffered progressive disease during follow-up; and objective response rate was 31.25%, and disease control rate was 87.5%. The median PFS was 179 days. Univariate and multivariate Cox analysis showed that the extrahepatic metastases and Child-Pugh score were independent prognostic factors of PFS. Twenty-two (68.75%) patients suffered adverse reactions. The main AEs were elevated transaminase (46.87%), thrombocytopenia (40.63%), hypoalbuminemia (28.13%), nausea and vomiting (21.88%), leukopenia (18.76%), abdominal pain (15.63%), hypertension (15.63%) and fever (15.63%). There were seven cases (21.88%) that had grade 3 or above AEs; Among them, two cases with elevated transaminase (6.25%), leukopenia, thrombocytopenia, nausea and vomiting, abdominal pain, and diarrhea occurred in one case respectively. Moreover, no treatment-related death was observed. Conclusions Hepatic arterial infusion of FOLFOX combined with lenvatinib and PD-1 inhibitor as the first-line treatment for HCC complicated with MaVI is effective, and adverse reactions are tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

Zhang,

et al. 2024

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) is one of the most malignant tumors with the top third cancer-related death (8.2%) (Bray et al 2018 ) worldwide. To date, the mortality rate of HCC is still rising globally (Wang et al 2023 ). Various risk factors can lead to the development of HCC, such as hepatic viral infection, alcohol abuse, and metabolic dysfunction (Barcena-Varela and Lujambio 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Alteration of serum bile acid profiles of HBV-related hepatocellular carcinoma identified by LC–MS/MS

Dai,

Zhu,

Chen

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Hepatocellular carcinoma closely related to metabolic disorders is a common and aggressive liver malignancy. The dysregulation of bile acid homeostasis has emerged as a key factor for the development and progression of HCC. We aimed to investigate the relationship between bile acids and HCC diagnosis and progression. Methods A total of 744 HBV-related patients (including 396 HCC patients and 348 patients with chronic liver diseases) were enrolled in the current study. The baseline characteristics of patients were collected from electronic medical records, and the levels of bile acid profiles were determined by LC–MS/MS. Propensity score matching analysis was conducted to reduce the effect of selection bias, and receiver operating characteristic analysis was performed to evaluate the clinical application values of bile acid. Results Significant differences were observed for most characteristics between the HCC group and the CLD group before PSM analysis. Patients with HCC were older and fatter (p < 0.05). After adjusting with a 1:1 ratio for age, gender and BMI, 42 HCC patients and 42 non-HCC patients were matched in 2 groups, respectively. The total bile acid level in HCC patients was lower than that in patients with chronic liver diseases before and after PSM analysis (p < 0.05). However, patients with HCC had significantly higher levels of DCA, LCA, and GLCA and lower levels of TCDCA, GUDCA, and TUDCA (p < 0.05, respectively). Besides, the TCDCA, TUDCA, GLCA, and GUDCA were significantly correlated with tumor procession. Moreover, the BAs profiles had a superior predictive ability for predicting the development of HCC even in patients with low serum AFP levels. Conclusion Patients with HCC had significantly lower levels of total bile acid, but higher levels of secondary bile acids (DCA, LCA, and GLCA). The levels of primary bile acid (TCDCA) were closely related to tumor size and stage, which indicated that the bile acids were involved in the HCC procession and had important clinical application values.

show abstract

Latest advances in hepatocellular carcinoma management and prevention through advanced technologies

Addissouky,

Sayed,

Ali

et al. 2024

Egypt Liver Journal

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is a common type of liver cancer, with a high mortality rate. Hepatocellular carcinoma is a type of liver cancer that can be effectively managed through early detection and accurate diagnosis, followed by a personalized treatment plan that may include surgical resection, liver transplantation, minimally-invasive techniques, immunotherapy, or targeted therapy depending on the stage and severity of the cancer. Main body of the abstract This paper discusses recent advances in the early detection, management, and prevention of HCC. The use of newer imaging techniques, such as Magnetic resonance imaging (MRI) and contrast-enhanced ultrasound, along with image segmentation technology and deep learning models, have greatly enhanced the accuracy of HCC detection and diagnosis. Minimally-invasive techniques, such as thermal ablation and radiofrequency ablation, have allowed for more precise and targeted destruction of tumors, while Nanoparticles, immunotherapy and targeted therapy have shown promise in the management of advanced stage HCC. The use of Artificial intelligence (AI) and machine learning has revolutionized HCC research, aiding in the identification of high-risk patients and predicting outcomes. Lifestyle modifications, such as weight management, alcohol avoidance, and hepatitis B vaccinations, can play a critical role in preventing HCC development. Short conclusion Recent advances in early detection, management, and prevention of HCC have shown promise in improving patient outcomes. The use of newer imaging techniques, minimally-invasive techniques, immunotherapy, targeted therapy, and AI and machine learning have greatly enhanced HCC research and management, while lifestyle modifications can play a critical role in prevention. However, further research is required to fully understand the potential benefits of nanoparticles, traditional Chinese medicine and herbal medicines in HCC treatment. Graphical Abstract

show abstract

Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Cited by 3 publications

References 31 publications

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

Alteration of serum bile acid profiles of HBV-related hepatocellular carcinoma identified by LC–MS/MS

Latest advances in hepatocellular carcinoma management and prevention through advanced technologies

Contact Info

Product

Resources

About